{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T06:03:03Z","timestamp":1774245783255,"version":"3.50.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diabetes mellitus is a globally prevalent disease, with an incidence of 5\u20137 new cases per 1000 person-years and no significant gender disparity. Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are recommended as second-line therapy after metformin in uncomplicated type 2 diabetes, whereas they are recommended as first-line treatment in patients with heart failure or other cardiorenal comorbidities. Given the recent introduction of SGLT-2 inhibitors, their increasing utilization, and the heterogeneity of existing literature, real-world evaluations of these agents are warranted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The MANDALORE study, a regional active pharmacovigilance project approved by the Italian Medicines Agency (AIFA), aims primarily to assess the drug utilization of gliflozins in clinical practice. The secondary objective is to analyze safety outcomes and investigate the determinants of treatment switching events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study will analyze medical records of patients who underwent at least one diabetes visit at the Metabolic Diseases and Diabetology\/Endocrinology Unit of Pisa University Hospital and the Diabetology and Metabolic Diseases Unit of Livorno Hospital. Inclusion criteria comprise that Tuscan patients receiving their first prescription for a gliflozin (index drug) between 2012 and 2021 (index date). Outcomes to be assessed include treatment switching, time to switching, line of therapy, dose adjustments, and time to dose change. Gliflozin utilization will be investigated, particularly in relation to concomitant interacting or contraindicated medications, and in patients requiring caution as specified by AIFA labeling and relevant tools. Incidence rates will be calculated for secondary safety outcomes, including adverse drug events (ADEs) leading to emergency room visits or hospitalization, non-serious ADEs, and specific ADEs as diabetic ketoacidosis, urinary and genital infections, gangrene, lower limb amputations, and neoplastic events. ADEs and therapeutic effectiveness observed in proximity to switching events will be investigated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The findings from the MANDALORE study are expected to elucidate critical aspects of gliflozin use in routine clinical practice, particularly within the Tuscan regional healthcare context, thereby providing valuable insights from the real-world for clinicians and healthcare systems.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1741084","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T05:21:24Z","timestamp":1774243284000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["SodiuM glucose cotrANsporter-2 (SGLT-2) inhibitors in the treatment of type II DiAbetes in Tuscany: utiLizatiOn patteRns, and relatEd clinical use evaluation; the MANDALORE study protocol"],"prefix":"10.3389","volume":"17","author":[{"given":"Irma","family":"Convertino","sequence":"first","affiliation":[{"name":"Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa","place":["Pisa, Italy"]},{"name":"Tuscan Regional Center of Pharmacovigilance","place":["Florence, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ersilia","family":"Lucenteforte","sequence":"additional","affiliation":[{"name":"Department of Statistics, Computer Science, Applications \u201cG. Parenti\u201d, University of Florence","place":["Florence, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janette","family":"Monzillo","sequence":"additional","affiliation":[{"name":"Tuscan Regional Center of Pharmacovigilance","place":["Florence, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Velo","sequence":"additional","affiliation":[{"name":"Tuscan Regional Center of Pharmacovigilance","place":["Florence, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiliano","family":"Cappello","sequence":"additional","affiliation":[{"name":"Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa","place":["Pisa, Italy"]},{"name":"Tuscan Regional Center of Pharmacovigilance","place":["Florence, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graziano","family":"Di Cianni","sequence":"additional","affiliation":[{"name":"Diabetology and Metabolic Diseases Unit, Azienda USL Toscana Nord-Ovest, Livorno Hospital","place":["Livorno, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Penno","sequence":"additional","affiliation":[{"name":"Metabolic diseases and Diabetology\/Endocrinology Unit, University Hospital of Pisa","place":["Pisa, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Fornai","sequence":"additional","affiliation":[{"name":"Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa","place":["Pisa, Italy"]},{"name":"Tuscan Regional Center of Pharmacovigilance","place":["Florence, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"B2","unstructured":"Il profilo assistenziale della popolazione con diabete\n          \n          \n          \n          2015"},{"key":"B3","unstructured":"La terapia del diabete mellito di tipo 2\n          \n          \n          \n          2022"},{"key":"B4","unstructured":"Diabete mellito tipo 2"},{"key":"B5","unstructured":"Standard di cura e Linee Guida della Societ\u00e0 Italiana di Diabetologia\n          \n          \n          2014"},{"key":"B6","unstructured":"Standard di cura e Linee Guida della Societ\u00e0 Italiana di Diabetologia\n          \n          \n          2016"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0033","article-title":"Buse JB; on behalf of the ADA\/EASD Consensus Panel. Management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"B11","unstructured":"Rapporto Nazionale OsMed 2019 sull\u2019uso dei farmaci in Italia\n          \n          \n          2020"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10245743","article-title":"Trajectories of adherence to biologic disease-modifying anti-rheumatic drugs in tuscan administrative databases: the pathfinder study","volume":"10","author":"Convertino","year":"2021","journal-title":"J Clin Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1244486","article-title":"Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy","volume":"14","author":"Convertino","year":"2023","journal-title":"Front Pharmacol"},{"key":"B14","volume-title":"Center For Drug Evaluation And Research Application Number: 202293Orig1s000 Medical Review(S)","year":"2013"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1884","article-title":"SGLT2 inhibitors may predispose to ketoacidosis","volume":"100","author":"Taylor","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4301-8","article-title":"SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System","volume":"60","author":"Fadini","year":"2017","journal-title":"Diabetologia"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2673","article-title":"Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial","volume":"36","author":"H\u00e4ring","year":"2013","journal-title":"Diabetes Care"},{"key":"B18","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/dom.12428","article-title":"Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55\u201380 years with type 2 diabetes","volume":"17","author":"Bode","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0467","article-title":"Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study","volume":"37","author":"Jabbour","year":"2014","journal-title":"Diabetes Care"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12825","article-title":"Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials","volume":"19","author":"Li","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"B21","unstructured":"ICH Official web site : ICH"},{"key":"B22","unstructured":"AIFA official website"},{"key":"B23","unstructured":"ICH Official web site : ICH"},{"key":"B24","volume-title":"AIFA official website","year":""}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1741084\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T05:21:26Z","timestamp":1774243286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1741084\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":24,"alternative-id":["10.3389\/fendo.2026.1741084"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1741084","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"article-number":"1741084"}}